Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis - Mycologie Moléculaire - Molecular Mycology Accéder directement au contenu
Article Dans Une Revue Open Forum Infectious Diseases Année : 2023

Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis

Résumé

Eculizumab, a recombinant humanized monoclonal antibody (mAb), is used for the treatment of patients (both adults and children) with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This mAb binds to complement protein 5 (C5), thereby inhibiting its cleavage. On the other hand, one of the C5 cleavage products, C5a, is a potent anaphylatoxin with proinflammatory properties, involved in antimicrobial surveillance. Administration of eculizumab has been reported to make patients more susceptible to infection by encapsulated bacteria. Here, we are reporting an adult case of disseminated infection due to the encapsulated yeast Cryptococcus neoformans following eculizumab therapy and discuss its pathogenesis.
Fichier principal
Vignette du fichier
ofad159.pdf (564.02 Ko) Télécharger le fichier
Origine : Publication financée par une institution
licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

hal-04335049 , version 1 (02-02-2024)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Olivier Lortholary, Carine El-Sissy, Jérémie Leporrier, Sarah Sze Wah Wong, Eric Dannaoui, et al.. Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis. Open Forum Infectious Diseases, 2023, 10 (4), ⟨10.1093/ofid/ofad159⟩. ⟨hal-04335049⟩
63 Consultations
6 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More